Johnson & Johnson
Approvals in the past 5 years: 5
Value of recent approvals: $24.26 billion
Percent of value from recent approvals: 10.23%
In pandemic times, Johnson & Johnson has become synonymous with the drugmaker’s COVID-19 vaccine. That’s no surprise given J&J’s single-shot jab, among only three pandemic vaccines that have scored an emergency nod in the U.S., is expected to bring in $2.5 billion in sales this year alone.
But in the background lurk five other recently approved J&J treatments worth $24.26 billion in net present value, according to a recent analysis from EvaluatePharma and Evaluate Vantage. That accounts for roughly 10.2% of the $237 billion in value for all of J&J's marketed drugs.
J&J has started 2021 with approvals for Ponvory to treat multiple sclerosis and Rybrevant, a non-small cell lung cancer (NSCLC) antibody. With Rybrevant's approval in May to treat NSCLC patients with a group of epidermal growth factor receptor (EGFR) mutations called exon 20, the drug became the first fully human, bispecific antibody in lung cancer. It's also J&J's first lung cancer medicine ever, the company said.
Other tyrosine kinase inhibitors (TKIs), such as AstraZeneca’s Tagrisso, target more common EGFR alterations at exon 19 and exon 21, but not exon 20, which is found in a slim 2% to 3% of patients. That leaves Rybrevant in its niche market all alone as J&J tries to broaden the drug’s use in the more common EGFR-mutated lung cancers. As of now, Rybrevant boasts a net present value of $1.4 billion, Evaluate says.
Rybrevant joins other lucrative additions to J&J's oncology portfolio in recent years, including prostate cancer med Erleada and bladder cancer drug Balversa. Those treatments, approved in 2018 and 2019, respectively, have served as much-needed boosts for J&J as its big-selling Zytiga has come under generic attack.
Erleada carries a net present value of $9.5 billion, while Evaluate analysts say Balversa is worth $1.1 billion.
Unlike Rybrevant, J&J's new MS drug Ponvory is certainly not the first in its field. The S1P modulator has been left to wrangle market share from existing heavyweights like Novartis, Bristol Myers Squibb, Sanofi and Biogen. That’s not to mention the CD20 rivals, including Roche's market-leading injectable Ocrevus and Novartis’ rival Kesimpta. Perhaps because of intense competition in the field, the Evaluate team doesn't assign any net present value to the drug.
But according to a recent Spherix Global Insights survey, Ponvory could gain market share in the next six months because of its ability to leave a patient’s system within a week. That's ideal for patients looking to start a family, Spherix said.
Picking up the bulk of J&J’s new drug value is its most recent blockbuster Tremfya, first approved in July 2017 for adults with moderate to severe plaque psoriasis and then psoriatic arthritis three years later. That drug carries a net present value of about $12 billion, Evaluate says.
Despite joining a crowded immunology field dominated by rivals like Novartis’ Cosentyx, Eli Lilly’s Taltz and AbbVie’s Humira, J&J’s IL-23 inhibitor has quickly gained steam. Tremfya earned its blockbuster badge in 2019 and raked in $1.3 billion in sales last year.
The drug is closing in on Cosentyx, which earned $4 billion last year, and Eli Lilly’s Taltz, which reaped $1.8 billion. Humira, however, far outpaces its rivals as the world’s best-selling drug, pulling in nearly $20 billion.
While J&J certainly has a well-established pharma group, the company is also working to build its burgeoning vaccine business. The company's one-dose COVID-19 vaccine has had its setbacks, but it's on pace to generate $2.5 billion in 2021. Pandemic vaccines aren't included in Evaluate's rankings because they aren't yet fully approved.
Aside from J&J's pandemic shot, the company is also advancing vaccines against HIV, Ebola and more. The drugmaker's Ebola shot scored European Commission approval last year.